Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.

Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

AC Immune (ACIU) delivered earnings and revenue surprises of +113.64% and +1,812.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?